Full Press Release Details
REGULATED INFORMATION
Nyxoah Raises $3 Million from its At-the-Market
Mont-Saint-Guibert, Belgium - April 13,
2023, 10:05pm CET / 4:05pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"),
a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea
(OSA), today announced that the Company raised $3.0 million in gross proceeds pursuant to the Company's $50 million at-the-market
("ATM") program established on December 22, 2022 at an issue price equal to the market price on the Nasdaq Global Market at
the time of the sale. The proceeds will be used for general corporate purposes.
The ordinary shares described above were sold
pursuant to the Company's shelf registration statement on Form F-3 (File No. 333-268955), previously filed with the Securities
and Exchange Commission ("SEC") on December 22, 2022, which became effective on January 6, 2023, and a prospectus supplement
dated January 6, 2023 and the accompanying prospectus the Company filed with the SEC in connection with the offer and sale of the Company's
common stock pursuant to the Controlled Equity OfferingSM Sales Agreement, dated as of December 22, 2022 with Cantor Fitzgerald & Co., as sales agent (prospectus@cantor.com).
Nyxoah is a medical technology company focused
on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution
is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world's
most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah
is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST
OSA study, the Genio system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah
received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated
in competitors' therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization
Caution - CE marked since 2019. Investigational
device in the United States. Limited by U.S. federal law to investigational use in the United States.
REGULATED INFORMATION
FORWARD-LOOKING STATEMENTS
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations
regarding the Genio system; planned and ongoing clinical studies of the Genio system; the potential advantages of the Genio
system; Nyxoah's goals with respect to the development, regulatory pathway and potential use of the Genio system; the utility
of clinical data in potentially obtaining FDA approval of the Genio system; and the Company's results of operations, financial condition,
liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties,
assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking
statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans
and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties
set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31,
2022, filed with the Securities and Exchange Commission ("SEC") on March 22, 2023, and subsequent reports that the Company
files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual
events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this
press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation
that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the
forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments
in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a
result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements
in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which
these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its
advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the
forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place
undue reliance on forward-looking statements, which speak only as of the date of this press release.
David DeMartino, Chief Strategy Officer